Published on

Pediatrics - Ewing Sarcoma

1. BASICS

Description

Ewing sarcoma is an aggressive malignant tumor of bone or soft tissue that predominantly affects children, adolescents, and young adults.

It belongs to the group of undifferentiated small round cell sarcomas and is defined by characteristic molecular abnormalities involving fusion genes that function as oncogenic transcription factors.

Principal Characteristics

Ewing sarcoma typically demonstrates:

  • Rapidly proliferating malignant cells.
  • Destructive bone or soft tissue growth.
  • Local invasion into adjacent structures.
  • Potential for early hematogenous metastasis.
  • Characteristic FET–ETS gene fusions.
  • Sensitivity to multiagent chemotherapy and radiotherapy.

Common Primary Sites

These include:

  • Pelvis.
  • Femur.
  • Tibia.
  • Humerus.
  • Ribs and chest wall.
  • Vertebral column.
  • Other bones and soft tissues.

Essential Principle

Suspected Ewing sarcoma requires urgent referral to a specialized pediatric sarcoma team before biopsy, surgery, or other invasive intervention.

2. HISTORICAL TERMINOLOGY

Ewing Sarcoma of Bone

The classical form arising within bone.

Extraskeletal Ewing Sarcoma

Ewing sarcoma arising in soft tissue rather than bone.

Peripheral Primitive Neuroectodermal Tumor

Historically used for tumors with greater neural differentiation.

Askin Tumor

Historically used for Ewing sarcoma involving the thoracopulmonary region or chest wall.

Contemporary Classification

These historical variants are generally grouped under Ewing sarcoma when they share the characteristic molecular profile.

Important Distinction

Not all small round cell sarcomas previously described as Ewing-like tumors are true Ewing sarcoma.

Clinical Importance

Modern molecular classification is essential because CIC-rearranged sarcoma, BCOR-altered sarcoma, and other round cell sarcomas are biologically distinct entities.

3. EPIDEMIOLOGY

General Occurrence

Ewing sarcoma is an uncommon cancer.

Pediatric Bone Malignancy

It is one of the most common primary malignant bone tumors in children and adolescents, second to osteosarcoma in many populations.

Age

Most diagnoses occur during the second decade of life.

Median Age

Approximately 15 years.

Sex Distribution

Males are affected somewhat more frequently than females.

Geographic Variation

Incidence differs substantially among populations.

Clinical Importance

Although rare, Ewing sarcoma should be considered when an adolescent has persistent unexplained focal bone pain.

4. INCIDENCE

General Principles

Ewing sarcoma accounts for a small proportion of childhood malignancies.

United States

Approximately several hundred cases are diagnosed annually across the pediatric and young adult age spectrum.

Annual Incidence

Rates in children are commonly estimated at a few cases per million annually.

Age Distribution

Incidence increases during later childhood and adolescence.

Population Variation

Reported rates depend on:

  • Age.
  • Geographic region.
  • Ancestry.
  • Diagnostic classification.
  • Cancer registry definitions.

Clinical Importance

The rarity of Ewing sarcoma contributes to delayed recognition when symptoms resemble common musculoskeletal conditions.

5. AGE DISTRIBUTION

Infancy

Ewing sarcoma is uncommon but possible.

Early Childhood

Cases occur, including extraskeletal tumors.

School-Age Children

Persistent bone pain or swelling may be the presenting feature.

Adolescence

The peak incidence occurs during adolescence.

Young Adulthood

Ewing sarcoma remains clinically important beyond the pediatric age range.

Older Adults

Uncommon presentations require careful pathological confirmation.

Clinical Importance

Age should inform clinical suspicion but must not be used to exclude the diagnosis.

6. SEX AND POPULATION PATTERNS

Sex Distribution

A modest male predominance is generally observed.

Population Differences

Ewing sarcoma is diagnosed less frequently in populations of African or East Asian ancestry than in populations of European ancestry.

Interpretation

Differences likely involve genetic susceptibility and complex population-level factors.

Clinical Importance

Population incidence patterns are not reliable enough to rule out Ewing sarcoma in an individual child.

7. RISK FACTORS

Sporadic Disease

Most cases arise without an identified predisposing clinical condition.

Genetic Susceptibility

Inherited genetic variation may influence risk.

Environmental Exposures

No specific environmental exposure has been established as a major preventable cause.

Family History

Most affected children do not have relatives with Ewing sarcoma.

Prior Cancer Therapy

Rare cases occur after treatment for another malignancy.

Clinical Importance

Ewing sarcoma is generally not caused by a child’s physical activity, a minor injury, or a recognizable lifestyle factor.

8. GENETIC SUSCEPTIBILITY

General Principles

Ewing sarcoma develops through acquired tumor-specific gene rearrangements.

Germline Variation

Certain inherited genetic variants influence susceptibility.

Familial Cancer Syndromes

Most cases are not associated with a recognizable hereditary cancer syndrome.

Hereditary Evaluation

Genetic counseling may be considered when there is:

  • Strong family cancer history.
  • Multiple primary malignancies.
  • Unusual clinical features.
  • Another indication for hereditary cancer assessment.

Important Distinction

A somatic EWSR1 fusion in tumor tissue does not mean that the alteration was inherited.

Clinical Importance

Most families do not require routine genetic testing solely because one child has Ewing sarcoma.

9. PREVENTION

General Principles

There is no established screening program that prevents Ewing sarcoma.

Lifestyle

No dietary, exercise, or supplement intervention has been shown to prevent the disease.

Routine Imaging

Not recommended for asymptomatic children.

Early Recognition

The principal practical opportunity is timely assessment of persistent suspicious symptoms.

Clinical Importance

Persistent focal bone pain, especially when associated with nighttime pain, swelling, or a mass, should not be repeatedly attributed to minor trauma without reassessment.

10. MOLECULAR PATHOGENESIS

General Principles

Ewing sarcoma is driven by characteristic chromosomal rearrangements that create oncogenic fusion proteins.

FET Family

Relevant genes include:

  • EWSR1.
  • FUS.
  • TAF15.

ETS Family

Important fusion partners include:

  • FLI1.
  • ERG.
  • ETV1.
  • ETV4.
  • FEV.

Fusion Proteins

These alter gene transcription and cellular regulatory pathways.

Cellular Consequences

Include:

  • Abnormal cell proliferation.
  • Impaired differentiation.
  • Altered chromatin regulation.
  • Malignant transformation.

Clinical Importance

Fusion-gene identification is central to confirming the modern diagnosis.

11. EWSR1::FLI1 FUSION

Description

EWSR1::FLI1 is the most frequent characteristic fusion in Ewing sarcoma.

Chromosomal Translocation

Usually results from:

t(11;22)(q24;q12).

Biological Effect

The fusion protein acts as an abnormal transcriptional regulator.

Frequency

Present in the majority of conventional Ewing sarcomas.

Diagnostic Value

Strongly supports Ewing sarcoma in the appropriate histological context.

Clinical Importance

Confirmation of EWSR1::FLI1 provides molecular evidence for the diagnosis, but the exact fusion subtype does not ordinarily determine standard treatment.

12. EWSR1::ERG AND RARE FUSIONS

EWSR1::ERG

The second most common characteristic fusion.

Chromosomal Rearrangement

Often involves chromosomes 21 and 22.

Other Fusions

Rare tumors harbor different FET–ETS combinations.

Diagnostic Testing

May require:

  • RNA sequencing.
  • Targeted next-generation sequencing.
  • Other fusion-detection methods.

Limitations of Restricted Testing

A negative test for EWSR1::FLI1 alone does not exclude Ewing sarcoma.

Clinical Importance

A broad molecular testing strategy may be necessary when the morphology suggests Ewing sarcoma but common fusion testing is negative.

13. EWING SARCOMA VERSUS EWING-LIKE SARCOMAS

General Principles

Several molecularly distinct sarcomas resemble Ewing sarcoma under the microscope.

CIC-Rearranged Sarcoma

Often involves CIC gene fusions and may behave aggressively.

BCOR-Altered Sarcoma

Includes tumors with BCOR-related genetic abnormalities.

EWSR1 Non-ETS Round Cell Sarcoma

Contains EWSR1 fusions involving partners outside the classical ETS family.

Diagnostic Importance

These entities may differ in:

  • Biology.
  • Treatment response.
  • Prognosis.
  • Clinical trial eligibility.

Clinical Importance

EWSR1 rearrangement detected by break-apart FISH alone is not sufficient to classify every small round cell tumor as Ewing sarcoma.

14. HISTOGENESIS AND TUMOR BIOLOGY

General Principles

The precise normal cell of origin remains an area of investigation.

Small Round Cell Morphology

Tumors typically contain relatively uniform malignant cells.

Proliferation

Growth may be rapid.

Local Invasion

Malignant cells may spread through bone and surrounding soft tissues.

Micrometastatic Disease

Occult systemic tumor cells may be present despite apparently localized imaging.

Clinical Importance

The likelihood of occult systemic disease explains why chemotherapy is essential even when the primary tumor appears completely resectable.

15. PRIMARY TUMOR SITES

Common Skeletal Sites

These include:

  • Pelvic bones.
  • Femur.
  • Tibia.
  • Fibula.
  • Humerus.
  • Ribs.
  • Vertebrae.

Soft Tissue Sites

May include:

  • Trunk.
  • Extremities.
  • Thoracic soft tissues.
  • Retroperitoneum.
  • Other locations.

Site-Dependent Symptoms

Presentation depends on local anatomy.

Clinical Importance

Tumor location affects biopsy planning, surgical feasibility, radiation decisions, and prognosis.

16. PELVIC EWING SARCOMA

General Principles

The pelvis is a common primary site.

Presenting Symptoms

May include:

  • Hip pain.
  • Buttock pain.
  • Back pain.
  • Limping.
  • Pelvic mass.
  • Difficulty walking.

Diagnostic Challenges

Deep tumors may not produce an obvious palpable mass.

Potential Local Effects

These include:

  • Compression of nerves.
  • Compression of pelvic organs.
  • Reduced mobility.

Clinical Importance

Unexplained persistent hip or pelvic pain warrants appropriate imaging when the clinical course is atypical.

17. FEMORAL AND LONG-BONE DISEASE

General Principles

Long-bone Ewing sarcoma frequently involves the diaphysis or metadiaphysis.

Symptoms

These include:

  • Localized pain.
  • Swelling.
  • Reduced activity.
  • Limp.
  • Tenderness.

Pathological Fracture

May occur when tumor destruction weakens bone.

Soft Tissue Extension

A mass may develop adjacent to the affected bone.

Clinical Importance

Long-bone lesions require careful evaluation for both local tumor extent and risk of fracture.

18. CHEST WALL EWING SARCOMA

Historical Term

Askin tumor has been used for Ewing sarcoma of the chest wall.

Typical Structures

May arise from:

  • Ribs.
  • Chest wall soft tissues.
  • Adjacent thoracic tissues.

Symptoms

These may include:

  • Chest wall pain.
  • Palpable mass.
  • Cough.
  • Dyspnea.
  • Pleural symptoms.

Local Extension

May involve the pleura or nearby thoracic structures.

Clinical Importance

Chest wall tumors require coordinated surgical, radiation, and pediatric oncology planning.

19. VERTEBRAL AND PARASPINAL DISEASE

General Principles

Ewing sarcoma may arise in vertebral or paraspinal structures.

Symptoms

These include:

  • Persistent back pain.
  • Night pain.
  • Radicular pain.
  • Weakness.
  • Sensory changes.

Spinal Canal Extension

May cause compression of the spinal cord or nerve roots.

Emergency Features

These include:

  • Progressive weakness.
  • Gait deterioration.
  • Bladder dysfunction.
  • Bowel dysfunction.

Clinical Importance

Suspected spinal cord compression is an oncological emergency requiring immediate MRI and specialist assessment.

20. EXTRASKELETAL EWING SARCOMA

Description

Extraskeletal Ewing sarcoma originates in soft tissue without a primary bone origin.

Common Locations

May include:

  • Extremities.
  • Trunk.
  • Thorax.
  • Pelvis.
  • Other soft tissues.

Presentation

Often involves a growing mass.

Imaging

MRI defines local extent and relationships to neurovascular structures.

Diagnosis

Requires the same rigorous molecular confirmation as skeletal Ewing sarcoma.

Clinical Importance

Extraskeletal disease is treated using similar multimodal principles but local-control decisions depend on anatomical location.

21. METASTATIC SPREAD

General Principles

Ewing sarcoma has a strong tendency for hematogenous dissemination.

Common Metastatic Sites

These include:

  • Lung.
  • Bone.
  • Bone marrow.

Less Common Sites

May include:

  • Regional lymph nodes.
  • Central nervous system.
  • Other organs.

Metastatic Presentation

Approximately one-quarter of patients have detectable metastases at diagnosis, depending on the population and staging methods.

Clinical Importance

Metastatic status at diagnosis is one of the strongest predictors of prognosis.

22. PULMONARY METASTASES

General Principles

The lungs are a common site of metastatic disease.

Clinical Presentation

Pulmonary metastases may be asymptomatic.

Advanced Disease

May cause:

  • Cough.
  • Dyspnea.
  • Chest discomfort.
  • Pleural symptoms.

Diagnosis

Chest CT is essential for staging.

Treatment

May involve systemic chemotherapy and selected pulmonary-directed local treatment.

Clinical Importance

Normal chest radiography does not adequately exclude pulmonary metastases at initial staging.

23. BONE METASTASES

General Principles

Ewing sarcoma may spread to distant skeletal sites.

Symptoms

Possible manifestations include:

  • Multifocal bone pain.
  • Limping.
  • Pathological fractures.
  • Functional impairment.

Detection

FDG-PET imaging is an important staging modality.

Alternative Imaging

Bone scintigraphy may be used in selected settings.

Clinical Importance

Bone metastatic disease generally indicates a higher-risk presentation than isolated localized disease.

24. BONE MARROW INVOLVEMENT

General Principles

Malignant cells may infiltrate bone marrow.

Clinical Findings

Possible manifestations include:

  • Anemia.
  • Thrombocytopenia.
  • Fatigue.
  • Bleeding.
  • Leukopenia.

Laboratory Findings

CBC abnormalities may raise suspicion.

Diagnostic Methods

May include marrow sampling in selected patients.

Contemporary Approach

Routine bilateral marrow biopsy may be omitted in some patients with otherwise localized disease after high-quality PET-based staging.

Clinical Importance

Bone marrow biopsy is no longer universally mandatory for every newly diagnosed patient when modern imaging adequately evaluates metastatic disease.

25. SKIP LESIONS

Description

Skip lesions are separate tumor deposits within the same bone or nearby skeletal compartment, discontinuous from the primary tumor.

Importance

May alter:

  • Surgical planning.
  • Radiation field.
  • Assessment of local disease extent.

MRI

Imaging of the entire involved bone is important.

Clinical Importance

Local MRI must extend beyond the immediately visible mass to identify discontinuous disease.

26. CLINICAL PRESENTATION

General Principles

Symptoms depend on the primary tumor site, size, and extent.

Most Common Symptom

Persistent localized pain.

Other Presentations

These include:

  • Swelling.
  • Palpable mass.
  • Limping.
  • Reduced joint movement.
  • Pathological fracture.
  • Fever.
  • Weight loss.

Advanced Disease

May produce systemic symptoms or organ-specific metastatic manifestations.

Clinical Importance

Early Ewing sarcoma can resemble common musculoskeletal conditions, making persistence and progression important warning signs.

27. BONE PAIN

General Principles

Bone pain is the most common presenting symptom.

Characteristics

May be:

  • Persistent.
  • Localized.
  • Progressive.
  • Worse at night.
  • Present at rest.

Early Disease

Pain may initially be intermittent.

Analgesic Response

Partial improvement with pain medication does not exclude malignancy.

Clinical Importance

Progressive focal bone pain persisting despite reasonable conservative management warrants imaging and reassessment.

28. NIGHT PAIN

General Principles

Pain that wakes a child from sleep can be concerning.

Associated Features

May include:

  • Local tenderness.
  • Swelling.
  • Limping.
  • Reduced activity.

Important Limitation

Night pain is not specific to malignancy.

Clinical Importance

Persistent focal night pain, particularly with swelling or systemic symptoms, should not be dismissed as ordinary growing pains.

29. SWELLING AND PALPABLE MASS

General Principles

A soft tissue mass may develop as a tumor extends beyond bone.

Physical Features

May be:

  • Firm.
  • Deep.
  • Tender.
  • Fixed to underlying structures.

Local Warmth

May occur because of vascularity and inflammation.

Size

May increase over time.

Clinical Importance

A progressively enlarging deep mass requires urgent imaging and specialist referral.

30. FEVER AND SYSTEMIC SYMPTOMS

General Principles

Ewing sarcoma can cause systemic symptoms more commonly than some other primary bone tumors.

Possible Features

These include:

  • Fever.
  • Fatigue.
  • Malaise.
  • Weight loss.
  • Reduced appetite.
  • Night sweats.

Differential Diagnosis

These findings may resemble infection.

Clinical Importance

Fever and elevated inflammatory markers do not exclude Ewing sarcoma or establish osteomyelitis.

31. LIMP AND MOBILITY CHANGES

General Principles

Tumors in the pelvis or lower extremities may alter gait.

Potential Findings

These include:

  • Antalgic gait.
  • Avoidance of weight-bearing.
  • Reduced participation in sports.
  • Difficulty climbing stairs.
  • Restricted joint motion.

Pathological Fracture

May produce sudden inability to bear weight.

Clinical Importance

Persistent unexplained limp in a child or adolescent requires appropriate assessment.

32. NEUROLOGICAL PRESENTATION

General Principles

Tumors near nerves or the spinal canal may produce neurological symptoms.

Symptoms

These include:

  • Weakness.
  • Numbness.
  • Radicular pain.
  • Gait disturbance.
  • Bowel dysfunction.
  • Bladder dysfunction.

Urgent Evaluation

Suspected spinal compression requires immediate MRI.

Clinical Importance

Neurological deterioration should not wait for routine outpatient oncology assessment.

33. PATHOLOGICAL FRACTURE

Description

A pathological fracture occurs through bone weakened by tumor.

Presentation

May include:

  • Sudden severe pain.
  • Deformity.
  • Swelling.
  • Inability to bear weight.

Management

Requires:

  • Immobilization.
  • Analgesia.
  • Orthopedic oncology assessment.
  • Tumor-specific treatment planning.

Important Precaution

Unplanned internal fixation can contaminate tissue planes and complicate definitive local control.

Clinical Importance

Suspected malignant pathological fracture should be managed through an orthopedic oncology team before definitive fixation whenever feasible.

34. HISTORY

General Principles

History should characterize the lesion and identify possible systemic or neurological involvement.

Pain

Document:

  • Location.
  • Duration.
  • Progression.
  • Night symptoms.
  • Relation to activity.

Swelling

Ask when a mass was first noticed.

Trauma

Determine whether a preceding injury adequately explains the symptoms.

Functional Changes

Review:

  • Limping.
  • School attendance.
  • Sports participation.
  • Daily activities.

Systemic Features

Ask about fever, weight loss, and fatigue.

Clinical Importance

A minor injury may draw attention to a preexisting lesion rather than cause the malignancy.

35. PHYSICAL EXAMINATION

General Principles

Examination should assess local disease and possible neurological or systemic complications.

General Assessment

Include:

  • Vital signs.
  • Growth.
  • Nutritional status.
  • General appearance.

Local Examination

Assess:

  • Tenderness.
  • Swelling.
  • Mass size.
  • Skin changes.
  • Range of motion.

Neurovascular Examination

Evaluate distal pulses, sensation, and motor function.

Spine

Assess neurological findings when axial disease is suspected.

Clinical Importance

Avoid vigorous palpation or manipulation of a potentially weakened bone.

36. RED FLAGS

Persistent Focal Bone Pain

Especially if progressive.

Night Pain

Particularly when associated with other abnormal findings.

Increasing Mass

A deep, enlarging swelling is concerning.

Pathological Fracture

Requires urgent orthopedic oncology evaluation.

Unexplained Limp

Especially with focal tenderness.

Fever and Bone Destruction

May represent infection or malignancy.

Neurological Deficits

May indicate spinal compression.

Clinical Importance

Suspicious imaging findings or a persistent unexplained bone lesion require referral to a sarcoma center before biopsy or surgery.

37. DIFFERENTIAL DIAGNOSIS

Malignant Conditions

These include:

  • Osteosarcoma.
  • Lymphoma of bone.
  • Leukemia.
  • Rhabdomyosarcoma.
  • CIC-rearranged sarcoma.
  • BCOR-altered sarcoma.
  • Neuroblastoma metastasis.
  • Other soft tissue sarcomas.

Benign or Nonmalignant Conditions

These include:

  • Osteomyelitis.
  • Stress fracture.
  • Traumatic injury.
  • Langerhans cell histiocytosis.
  • Benign bone tumors.
  • Chronic recurrent multifocal osteomyelitis.

Clinical Importance

Imaging alone cannot always distinguish Ewing sarcoma from infection or other malignancy.

38. OSTEOMYELITIS

General Principles

Osteomyelitis can closely resemble Ewing sarcoma.

Shared Features

These include:

  • Bone pain.
  • Fever.
  • Swelling.
  • Elevated inflammatory markers.
  • Destructive radiographic lesions.

Diagnostic Challenges

Both can produce periosteal reaction and adjacent soft tissue abnormalities.

Important Distinction

Failure to improve with appropriate infection treatment requires reassessment.

Clinical Importance

A destructive bone lesion should not undergo unplanned surgical drainage or prolonged empirical antibiotic treatment without considering malignancy.

39. OSTEOSARCOMA

General Principles

Osteosarcoma is another important primary malignant bone tumor in adolescents.

Typical Location

Often involves the metaphysis of long bones.

Imaging

May show osteoid-producing matrix and aggressive periosteal reaction.

Histology

Malignant osteoid production supports osteosarcoma.

Ewing Sarcoma

More often demonstrates small round cells and characteristic fusion genes.

Clinical Importance

Correct histological classification is essential because the chemotherapy regimens differ.

40. SMALL ROUND CELL SARCOMAS

General Principles

Several sarcomas share the appearance of small round malignant cells.

Important Entities

Include:

  • Ewing sarcoma.
  • CIC-rearranged sarcoma.
  • BCOR-altered sarcoma.
  • Desmoplastic small round cell tumor.
  • Some rhabdomyosarcomas.

Diagnostic Tools

Require integration of:

  • Morphology.
  • Immunohistochemistry.
  • Molecular pathology.

Clinical Importance

An undifferentiated round cell tumor should not be treated as conventional Ewing sarcoma without appropriate diagnostic confirmation.

41. INITIAL IMAGING

General Principles

Plain radiographs are usually the first imaging investigation for persistent focal bone symptoms.

Standard Views

Obtain at least two orthogonal views when appropriate.

Suspicious Features

These include:

  • Aggressive bone destruction.
  • Permeative or moth-eaten appearance.
  • Periosteal reaction.
  • Soft tissue mass.
  • Cortical destruction.

Next Step

Urgent MRI and sarcoma specialist referral.

Clinical Importance

Normal or equivocal early radiographs do not completely exclude a malignant bone lesion when symptoms persist.

42. PLAIN RADIOGRAPHIC FINDINGS

Permeative Destruction

Multiple small areas of bone destruction may create a moth-eaten pattern.

Periosteal Reaction

May be aggressive and layered.

Onion-Skin Appearance

Reflects successive layers of periosteal new bone formation.

Codman Triangle

Raised periosteum may create an angular reactive bone appearance.

Cortical Destruction

May be visible in advanced lesions.

Soft Tissue Component

May accompany bone abnormalities.

Clinical Importance

The onion-skin appearance is suggestive but not specific for Ewing sarcoma.

43. MRI OF THE PRIMARY SITE

General Principles

MRI is the preferred modality for defining local tumor extent.

Assessment

Should characterize:

  • Intramedullary tumor extent.
  • Soft tissue extension.
  • Neurovascular involvement.
  • Joint relationships.
  • Adjacent structures.
  • Skip lesions.

Contrast

Contrast-enhanced sequences may aid characterization and biopsy targeting.

Field of View

For long-bone disease, imaging the full involved bone and relevant adjacent joints is important.

Clinical Importance

MRI should generally be completed before biopsy to support accurate staging and procedural planning.

44. CT OF THE PRIMARY SITE

General Principles

CT can complement MRI.

Potential Uses

These include:

  • Defining cortical bone destruction.
  • Evaluating complex pelvic bone anatomy.
  • Surgical planning.
  • Assessing mineralization.

Limitations

MRI is generally superior for soft tissue and marrow extent.

Radiation Exposure

Consider cumulative radiation in pediatric patients.

Clinical Importance

CT should address a specific diagnostic or planning question rather than replace comprehensive MRI.

45. METASTATIC STAGING

General Principles

Complete staging is required before definitive treatment.

Main Objectives

Determine:

  • Primary tumor extent.
  • Pulmonary metastases.
  • Skeletal metastases.
  • Bone marrow involvement.
  • Other metastatic sites when suspected.

Standard Investigations

Typically include:

  • Chest CT.
  • FDG-PET/CT or another suitable whole-body staging modality.
  • MRI of the primary region.

Clinical Importance

The distinction between localized and metastatic disease is central to treatment planning and prognosis.

46. CHEST CT

General Principles

Chest CT is the principal imaging modality for detecting pulmonary metastases.

Findings

May demonstrate:

  • Pulmonary nodules.
  • Pleural abnormalities.
  • Other thoracic involvement.

Indeterminate Nodules

Small nodules may be difficult to classify.

Follow-Up

Requires multidisciplinary interpretation.

Clinical Importance

Not every small pulmonary nodule is metastatic, but suspicious findings must be incorporated into staging decisions.

47. FDG-PET IMAGING

General Principles

Fluorodeoxyglucose PET evaluates metabolically active disease.

Uses

Include:

  • Initial metastatic staging.
  • Detection of skeletal lesions.
  • Selected response assessment.
  • Investigation of suspected recurrence.

PET/CT

Provides anatomical and metabolic information.

Limitations

Inflammation can produce false-positive uptake.

Small lesions may be missed.

Clinical Importance

PET is an important contemporary staging tool, particularly for skeletal metastatic disease.

48. BONE SCINTIGRAPHY

General Principles

Technetium-based bone scintigraphy has historically been used to detect skeletal metastases.

Contemporary Role

May be used when PET imaging is unavailable or unsuitable.

Limitations

Sensitivity and specificity vary by lesion characteristics.

Clinical Importance

PET-based staging has reduced the routine need for bone scans in many centers.

49. BONE MARROW ASPIRATION AND BIOPSY

Historical Approach

Bilateral marrow aspirates and biopsies were routinely performed in many staging protocols.

Contemporary Practice

Modern PET-based imaging can detect many clinically important marrow and skeletal lesions.

Selected Omission

Marrow sampling may be omitted in selected patients with otherwise localized disease after high-quality staging.

Indications for Sampling

Consider when:

  • Imaging is suspicious.
  • Blood counts are abnormal.
  • Protocols require it.
  • Findings would alter treatment.

Clinical Importance

Bone marrow sampling should be individualized rather than assumed mandatory in every patient.

50. DIAGNOSTIC BIOPSY PLANNING

General Principles

Biopsy must be planned by the sarcoma team responsible for definitive local treatment.

Objectives

Obtain sufficient tissue while avoiding unnecessary contamination.

Biopsy Tract

Should be positioned so that it can be removed during definitive surgery when feasible.

Important Precautions

Avoid:

  • Unplanned transverse incisions.
  • Contamination of multiple compartments.
  • Injury to major neurovascular structures.
  • Inadequate tissue acquisition.

Clinical Importance

An improperly planned biopsy can jeopardize limb-salvage surgery and compromise local tumor control.

51. BIOPSY TECHNIQUES

Image-Guided Core Biopsy

Often appropriate when performed by an experienced interventional radiologist and sarcoma team.

Open Biopsy

May be needed when core biopsy is insufficient.

Tissue Handling

Samples should be allocated for:

  • Histology.
  • Immunohistochemistry.
  • Molecular testing.
  • Additional studies when indicated.

Repeat Biopsy

Occasionally required if the original tissue is nondiagnostic.

Clinical Importance

Obtaining enough tissue for molecular confirmation is essential.

52. HISTOPATHOLOGY

General Principles

Conventional Ewing sarcoma typically appears as a malignant small round blue cell tumor.

Microscopic Features

Often include:

  • Relatively uniform small round cells.
  • High nuclear-to-cytoplasmic ratio.
  • Fine chromatin.
  • Scant cytoplasm.
  • Variable necrosis.

Glycogen

Tumor cells may contain cytoplasmic glycogen.

Morphological Variability

Some tumors show atypical or differentiated features.

Clinical Importance

Morphology is suggestive but insufficient for modern definitive classification without supporting immunophenotypic and molecular evidence.

53. IMMUNOHISTOCHEMISTRY

CD99

Often shows strong diffuse membranous expression.

NKX2.2

May provide additional support.

Other Markers

Used to exclude:

  • Lymphoid malignancy.
  • Rhabdomyosarcoma.
  • Neuroblastoma.
  • Carcinoma.
  • Other small round cell tumors.

Important Limitation

CD99 is not specific for Ewing sarcoma.

Clinical Importance

CD99 positivity alone must not be used to establish Ewing sarcoma.

54. MOLECULAR CONFIRMATION

General Principles

Fusion-gene testing is strongly recommended.

Common Methods

These include:

  • Fluorescence in situ hybridization.
  • RT-PCR.
  • RNA sequencing.
  • Next-generation sequencing.

EWSR1 Break-Apart FISH

Detects EWSR1 rearrangement but does not necessarily identify the fusion partner.

RNA-Based Methods

May identify specific fusion transcripts.

Negative Results

May reflect:

  • A rare fusion.
  • Technical limitations.
  • Another tumor entity.

Clinical Importance

Integrating molecular testing with histology is essential for accurate diagnosis.

55. LABORATORY EVALUATION

Complete Blood Count

Assesses baseline marrow function.

Kidney Function

Necessary before nephrotoxic chemotherapy.

Liver Function

Helps guide treatment safety.

Electrolytes

Assess baseline metabolic status.

Lactate Dehydrogenase

May be elevated and carries prognostic information in some studies.

Additional Testing

May include pregnancy assessment and other tests when clinically appropriate.

Clinical Importance

No blood biomarker alone establishes the diagnosis of Ewing sarcoma.

56. PRETREATMENT CARDIAC EVALUATION

General Principles

Anthracycline chemotherapy can cause cardiac injury.

Baseline Assessment

May include:

  • Echocardiogram.
  • Left ventricular systolic function.
  • ECG when indicated.
  • Cardiac history.

Risk Factors

Include prior cardiac disease or chest irradiation.

Long-Term Monitoring

Depends on cumulative treatment exposure and survivorship guidelines.

Clinical Importance

Baseline cardiac assessment is essential before doxorubicin-containing treatment.

57. PRETREATMENT FUNCTIONAL ASSESSMENT

General Principles

Document function before chemotherapy and local treatment.

Assessment

May include:

  • Mobility.
  • Joint range of motion.
  • Neurological function.
  • Pain.
  • Activities of daily living.

Rehabilitation Planning

Early physical therapy assessment may be useful.

Nutrition

Review weight, dietary intake, and nutritional risks.

Clinical Importance

Baseline function supports rehabilitation planning and helps identify treatment-related changes.

58. STAGING AND RISK STRATIFICATION

Localized Disease

No detectable distant metastases on staging.

Metastatic Disease

Evidence of distant tumor spread.

Additional Prognostic Factors

These include:

  • Tumor size.
  • Tumor location.
  • Age.
  • LDH.
  • Response to chemotherapy.
  • Adequacy of local control.

Clinical Importance

Risk stratification should be performed by a multidisciplinary sarcoma team using the current treatment protocol.

59. TREATMENT PRINCIPLES

General Principles

Curative treatment usually requires a combination of:

  1. Systemic chemotherapy.
  2. Local control by surgery, radiation, or both.
  3. Additional systemic therapy after local control.
  4. Treatment of selected metastatic sites.

Treatment Setting

Care should occur in a specialized pediatric or adolescent and young adult sarcoma center.

Clinical Trials

Enrollment in appropriate clinical trials should be offered when available.

Clinical Importance

Surgery or radiation alone is insufficient for most patients because occult micrometastatic disease is common.

60. INTERVAL-COMPRESSED CHEMOTHERAPY

General Principles

Interval-compressed chemotherapy is a major standard treatment strategy for localized Ewing sarcoma.

Treatment Schedule

Chemotherapy cycles are generally administered approximately every two weeks when blood count recovery permits.

Regimen

Alternating combinations commonly include:

  • Vincristine, doxorubicin, and cyclophosphamide.
  • Ifosfamide and etoposide.

Abbreviation

VDC/IE.

Growth Factor Support

Usually required to support interval compression.

Clinical Importance

Interval-compressed VDC/IE is an established standard backbone for many children and adolescents with newly diagnosed Ewing sarcoma.

61. VDC CHEMOTHERAPY

Vincristine

A microtubule inhibitor.

Doxorubicin

An anthracycline.

Cyclophosphamide

An alkylating agent.

Principal Toxicities

Include:

  • Myelosuppression.
  • Nausea.
  • Mucositis.
  • Neuropathy.
  • Cardiotoxicity.
  • Hemorrhagic cystitis.
  • Fertility impairment.

Administration

Doses are prescribed using protocol-specific body surface area calculations and organ function adjustments.

Clinical Importance

VDC must be administered under an oncology protocol with appropriate supportive care.

62. IE CHEMOTHERAPY

Ifosfamide

An alkylating agent.

Etoposide

A topoisomerase II inhibitor.

Principal Toxicities

Include:

  • Neutropenia.
  • Infection.
  • Kidney tubular injury.
  • Neurotoxicity.
  • Hemorrhagic cystitis.
  • Secondary leukemia risk.

Uroprotection

Mesna and appropriate hydration are used with ifosfamide.

Monitoring

Includes kidney function, electrolytes, neurological status, and urine assessment.

Clinical Importance

IE treatment requires close inpatient or specialized outpatient monitoring depending on the protocol.

63. CHEMOTHERAPY SCHEDULING

General Principles

Treatment is typically divided into induction and consolidation phases.

Induction

Aims to reduce primary tumor size and treat occult systemic disease.

Local Control

Usually occurs after an initial period of chemotherapy.

Consolidation

Continues systemic therapy after local treatment.

Cycle Number

Common protocols use approximately 14 cycles of interval-compressed VDC/IE, although regimen duration varies.

Important Limitation

Increasing the number of cycles does not automatically improve outcomes and may increase toxicity.

Clinical Importance

The exact schedule should follow the selected evidence-based cooperative group protocol.

64. CHEMOTHERAPY DOSE SAFETY

General Principles

Ewing sarcoma chemotherapy uses high-risk cytotoxic medications.

Dosing Basis

Typically depends on:

  • Body surface area.
  • Treatment protocol.
  • Organ function.
  • Blood count recovery.
  • Prior toxicity.

Administration

Requires:

  • Independent dose verification.
  • Appropriate vascular access.
  • Infusion precautions.
  • Extravasation protocols.

Vincristine

Must only be administered intravenously using institutional safety procedures.

Clinical Importance

Chemotherapy doses must not be improvised from general mg/kg guidance or administered outside a specialized oncology service.

65. LOCAL CONTROL

General Principles

Local treatment aims to eradicate the primary tumor.

Main Approaches

These include:

  • Surgery.
  • Definitive radiation therapy.
  • Surgery followed by radiation in selected cases.

Selection Factors

Include:

  • Tumor site.
  • Size.
  • Neurovascular involvement.
  • Expected function.
  • Response to chemotherapy.
  • Feasibility of negative margins.
  • Long-term treatment effects.

Clinical Importance

Local-control planning should involve orthopedic oncology, radiation oncology, pediatric oncology, and relevant surgical specialists.

66. SURGICAL RESECTION

General Principles

Surgery is preferred when the tumor can be completely removed with acceptable morbidity.

Goal

Achieve negative margins while preserving as much normal function as possible.

Surgical Planning

Must consider:

  • Original tumor extent.
  • Response to chemotherapy.
  • Biopsy tract.
  • Relevant anatomical compartments.

Pathology

Resected tissue provides information on margins and chemotherapy response.

Clinical Importance

An apparently smaller tumor after chemotherapy does not justify disregarding the original tumor extent during local-control planning.

67. LIMB-SALVAGE SURGERY

General Principles

Limb salvage is frequently feasible for extremity tumors.

Techniques

May involve:

  • Wide resection.
  • Endoprosthetic reconstruction.
  • Bone grafting.
  • Allograft reconstruction.
  • Other orthopedic reconstruction.

Advantages

Potential preservation of limb function.

Limitations

Complications may include:

  • Infection.
  • Mechanical failure.
  • Nonunion.
  • Growth-related problems.

Clinical Importance

Limb-salvage surgery should achieve oncological safety as well as functional benefit.

68. AMPUTATION AND ROTATIONPLASTY

General Principles

Amputation is less commonly necessary but remains appropriate in selected cases.

Indications

May include:

  • Unresectable neurovascular involvement.
  • Inadequate margins with limb salvage.
  • Severe local complications.
  • Poor expected function after reconstruction.

Rotationplasty

May be useful for selected lower limb tumors.

Rehabilitation

Requires prosthetic and physical therapy services.

Clinical Importance

The choice should prioritize survival, long-term function, and the patient’s individual goals.

69. RADIATION THERAPY

General Principles

Ewing sarcoma is radiosensitive.

Indications

Radiotherapy may be used for:

  • Definitive local control.
  • Positive or inadequate surgical margins.
  • Selected high-risk local situations.
  • Certain metastatic sites.

Techniques

May include modern conformal methods.

Treatment Planning

Requires careful consideration of:

  • Tumor extent.
  • Nearby critical organs.
  • Growth plates.
  • Long-term secondary cancer risk.

Clinical Importance

Radiotherapy is an important curative treatment option when surgery would be unsafe or excessively disabling.

70. PROTON THERAPY AND MODERN RADIATION TECHNIQUES

General Principles

Advanced radiotherapy techniques may reduce exposure of surrounding normal tissues.

Proton Therapy

May offer dosimetric advantages in selected anatomical locations.

Potential Benefits

Include reduced dose to:

  • Certain organs at risk.
  • Growth-sensitive structures.
  • Adjacent healthy tissues.

Important Limitation

Availability and long-term comparative outcomes vary.

Clinical Importance

Modality selection should be based on individualized treatment planning rather than assuming one technique is always superior.

71. METASTATIC DISEASE TREATMENT

General Principles

Metastatic Ewing sarcoma requires systemic therapy and consideration of local treatment to the primary tumor and metastatic sites.

Chemotherapy

VDC/IE-based therapy remains an important backbone.

Local Control

May include:

  • Surgery.
  • Radiation.
  • Selected treatment of metastatic lesions.

Lung Metastases

Whole-lung irradiation may be considered in appropriate patients.

Bone Metastases

Selected metastatic sites may receive radiation.

Clinical Importance

Metastatic treatment requires individualized multidisciplinary planning and discussion of prognosis and clinical trials.

72. WHOLE-LUNG IRRADIATION

General Principles

Whole-lung irradiation may be used in selected patients with pulmonary metastatic disease.

Purpose

Targets potential residual pulmonary microscopic disease.

Timing

Usually coordinated with systemic therapy and other local treatments.

Pediatric Considerations

Risks include:

  • Pneumonitis.
  • Reduced lung capacity.
  • Long-term pulmonary fibrosis.
  • Additional late effects.

Clinical Importance

Whole-lung irradiation decisions should consider metastatic pattern, treatment response, age, and the applicable protocol.

73. RELAPSED OR REFRACTORY EWING SARCOMA

General Principles

Relapse may occur locally, distantly, or at multiple sites.

Common Sites

Include:

  • Lung.
  • Bone.
  • Original tumor site.

Prognosis

Relapsed disease is more difficult to cure.

Treatment Options

May include:

  • Salvage chemotherapy.
  • Surgery.
  • Radiotherapy.
  • Clinical trials.
  • Symptom-directed treatment.

Clinical Importance

There is no single universally curative standard regimen for all relapsed Ewing sarcoma.

74. SALVAGE CHEMOTHERAPY

Potential Regimens

May include combinations involving:

  • Irinotecan.
  • Temozolomide.
  • Cyclophosphamide.
  • Topotecan.
  • High-dose ifosfamide.
  • Other agents.

Selection Factors

Include:

  • Previous chemotherapy exposure.
  • Interval to relapse.
  • Organ function.
  • Disease distribution.
  • Patient preferences.
  • Clinical trial availability.

Evidence

Responses occur, but long-term disease control remains challenging.

Clinical Importance

Salvage regimens should be chosen by an experienced pediatric sarcoma team.

75. INVESTIGATIONAL AND TARGETED THERAPIES

General Principles

Research is investigating treatments directed at tumor biology and immune mechanisms.

Investigational Strategies

Include:

  • Novel cytotoxic combinations.
  • Targeted pathway inhibitors.
  • Fusion-associated therapeutic strategies.
  • Immunotherapies.
  • Cellular therapies.
  • New radiopharmaceutical approaches.

Important Limitation

No targeted therapy has replaced VDC/IE as established initial curative systemic treatment.

Clinical Trials

Should be considered when appropriate.

Clinical Importance

Experimental approaches must be distinguished clearly from standard-of-care therapy.

76. SUPPORTIVE ONCOLOGY CARE

General Principles

Supportive care is essential throughout treatment.

Core Components

Include:

  • Antiemetic therapy.
  • Growth factor support.
  • Infection prevention.
  • Blood product support.
  • Pain control.
  • Nutrition.
  • Rehabilitation.
  • Psychosocial care.

Multidisciplinary Team

May include:

  • Pediatric oncologist.
  • Oncology nurse.
  • Pharmacist.
  • Dietitian.
  • Social worker.
  • Physical therapist.
  • Psychologist.

Clinical Importance

Effective supportive care improves treatment tolerance and reduces preventable complications.

77. FEBRILE NEUTROPENIA

General Principles

Chemotherapy can cause profound neutropenia.

Warning Symptoms

Include:

  • Fever.
  • Chills.
  • Ill appearance.
  • New respiratory symptoms.
  • Central line symptoms.

Emergency Definition

Fever in a child with chemotherapy-associated neutropenia is a medical emergency.

Management

Requires:

  • Prompt assessment.
  • Blood cultures.
  • Empiric IV broad-spectrum antibiotics.
  • Risk-based inpatient or specialized outpatient management.

Clinical Importance

Families must contact the oncology team immediately for fever during periods of neutropenia rather than treating it at home and waiting.

78. HEMATOLOGICAL SUPPORT

General Principles

Myelosuppressive chemotherapy may cause anemia and thrombocytopenia.

Red Blood Cell Transfusion

May be required for symptomatic or severe anemia.

Platelet Transfusion

May be necessary with severe thrombocytopenia, bleeding, or procedures.

Growth Factors

G-CSF supports neutrophil recovery.

Monitoring

CBC is checked according to the treatment schedule.

Clinical Importance

Transfusion decisions should follow oncology protocols and the patient’s clinical condition.

79. NAUSEA, MUCOSITIS, AND NUTRITION

General Principles

Chemotherapy can substantially affect gastrointestinal function.

Antiemetic Therapy

Typically involves protocol-based medications such as:

  • 5-HT3 receptor antagonists.
  • Dexamethasone when appropriate.
  • Neurokinin-1 receptor antagonists for highly emetogenic treatment.

Mucositis

Requires:

  • Oral care.
  • Analgesia.
  • Hydration.
  • Infection monitoring.

Nutrition

Dietitian assessment may prevent or treat malnutrition.

Clinical Importance

Supportive treatment should be proactive rather than started only after severe symptoms develop.

80. RENAL AND BLADDER PROTECTION

General Principles

Ifosfamide and cyclophosphamide may injure the urinary tract.

Mesna

Used for uroprotection according to the chemotherapy protocol.

Hydration

Helps reduce urinary metabolite concentration.

Monitoring

Includes:

  • Urine output.
  • Urinalysis.
  • Kidney function.
  • Electrolytes.

Ifosfamide Toxicity

May cause renal tubular dysfunction and electrolyte wasting.

Clinical Importance

Hematuria, reduced urine output, or significant electrolyte abnormalities require prompt oncology assessment.

81. CARDIOTOXICITY PREVENTION

General Principles

Doxorubicin may cause cumulative cardiac injury.

Baseline Assessment

Obtain echocardiography before treatment.

Treatment Monitoring

Frequency depends on:

  • Anthracycline dose.
  • Symptoms.
  • Cardiac risk factors.
  • Institutional protocol.

Dexrazoxane

May be used as cardioprotection in selected patients according to the oncology protocol.

Long-Term Surveillance

Required according to cumulative anthracycline exposure and cardiac radiation dose.

Clinical Importance

Annual echocardiography is not universally required for every survivor; surveillance intervals should follow risk-based survivorship guidelines.

82. FERTILITY PRESERVATION

General Principles

Alkylating chemotherapy may impair future fertility.

Counseling

Should occur before starting treatment whenever feasible.

Postpubertal Boys

Sperm cryopreservation may be an option.

Postpubertal Girls

Options may include:

  • Oocyte cryopreservation.
  • Embryo cryopreservation in appropriate circumstances.

Prepubertal Children

Some tissue preservation approaches remain investigational or have limited availability.

Time Sensitivity

Fertility preservation must be coordinated without unsafe delays in cancer treatment.

Clinical Importance

All eligible patients and families should be offered age-appropriate fertility counseling before gonadotoxic treatment begins.

83. REHABILITATION

General Principles

Cancer and its treatment may impair mobility, strength, and endurance.

Physical Therapy

May address:

  • Gait.
  • Muscle weakness.
  • Range of motion.
  • Balance.
  • Strength.
  • Functional independence.

Occupational Therapy

May help with activities of daily living.

Prosthetic Services

Required after amputation or rotationplasty when indicated.

Pain Management

Supports participation in rehabilitation.

Clinical Importance

Rehabilitation should begin early and continue through survivorship when necessary.

84. PSYCHOSOCIAL SUPPORT

General Principles

A cancer diagnosis during childhood or adolescence can substantially affect emotional and social development.

Potential Concerns

Include:

  • Anxiety.
  • Depression.
  • Body image.
  • School disruption.
  • Social isolation.
  • Fear of recurrence.

Family Support

Caregivers may experience financial and psychological stress.

Specialist Services

May include:

  • Psychology.
  • Psychiatry.
  • Social work.
  • Peer support.
  • Educational support.

Clinical Importance

Psychosocial care is a standard component of comprehensive pediatric oncology treatment.

85. PALLIATIVE CARE

General Principles

Palliative care focuses on quality of life and symptom relief.

Timing

May be appropriate from diagnosis alongside curative treatment for patients with significant symptom burden.

Services

Include:

  • Pain management.
  • Symptom control.
  • Family counseling.
  • Care coordination.
  • Goals-of-care discussions.

Advanced Disease

May become particularly important when cure is unlikely.

Clinical Importance

Palliative care is not synonymous with stopping cancer treatment.

86. HOSPITAL ADMISSION

General Principles

Many treatment phases require inpatient or closely supervised specialized care.

Admission Indications

Include:

  • Intensive chemotherapy.
  • Febrile neutropenia.
  • Severe pain.
  • Pathological fracture.
  • Spinal cord compression.
  • Dehydration.
  • Serious infection.
  • Organ dysfunction.

Surgical Care

Requires perioperative monitoring.

Clinical Importance

Admission and discharge decisions should follow the oncology treatment protocol and clinical stability.

87. NURSING CONSIDERATIONS

General Principles

Oncology nursing care includes chemotherapy safety and early complication recognition.

Monitoring

Includes:

  • Vital signs.
  • Pain.
  • Fluid balance.
  • Infection signs.
  • Neurological status.
  • Urine output.
  • Central line function.

Education

Teach families about:

  • Fever precautions.
  • Medication administration.
  • Bleeding symptoms.
  • Chemotherapy toxicity.
  • Emergency contact procedures.

Clinical Importance

Specialized pediatric oncology nursing is central to safe multimodal treatment.

88. FOLLOW-UP RECOMMENDATIONS

During Treatment

Assess:

  • Clinical response.
  • CBC.
  • Organ function.
  • Chemotherapy toxicity.
  • Primary tumor imaging.

After Treatment

Schedule regular visits for:

  • Recurrence surveillance.
  • Local functional assessment.
  • Pulmonary imaging.
  • Late-effect evaluation.

Early Survivorship

Visits are commonly more frequent during the first two years.

Later Survivorship

Intervals generally lengthen over time.

Clinical Importance

Follow-up should be individualized according to initial disease extent, local treatment, recurrence risk, and treatment exposures.

89. RECURRENCE SURVEILLANCE

General Principles

Relapse risk is greatest during the first several years after treatment.

Local Surveillance

May involve:

  • Clinical examination.
  • MRI or radiographs of the primary site.

Pulmonary Surveillance

May involve:

  • Chest radiography.
  • CT in selected circumstances.

Other Imaging

PET or other whole-body imaging may be indicated when recurrence is suspected.

Important Limitation

Routine intensive whole-body imaging for every survivor may increase radiation exposure without proven benefit.

Clinical Importance

A surveillance plan should balance early detection with imaging burden and long-term risk.

90. LONG-TERM SURVIVORSHIP

General Principles

Survivors require lifelong attention to treatment-related health risks.

Important Domains

Include:

  • Cardiac health.
  • Kidney function.
  • Fertility.
  • Bone and joint function.
  • Pulmonary health.
  • Endocrine function.
  • Secondary cancers.
  • Mental health.

Survivorship Plan

Should document:

  • Chemotherapy agents.
  • Cumulative doses.
  • Radiation fields and doses.
  • Surgical procedures.
  • Recommended surveillance.

Clinical Importance

Late-effect monitoring should be exposure-based rather than identical for every survivor.

91. PATIENT AND FAMILY EDUCATION

General Principles

Families should understand the need for coordinated multimodal therapy.

Key Messages

Explain that:

  • Ewing sarcoma is a malignant tumor.
  • Chemotherapy is essential.
  • Local control is also required.
  • Treatment may extend over many months.
  • Fever during neutropenia requires urgent action.
  • Long-term follow-up is necessary.

Activity

Follow orthopedic restrictions when fracture risk exists.

Medication Safety

Avoid unapproved supplements or treatments that may interfere with chemotherapy.

Clinical Importance

Clear education supports adherence and early recognition of complications.

92. PROGNOSIS

General Outlook

Prognosis depends strongly on disease extent at diagnosis and response to treatment.

Localized Disease

Modern multimodal therapy produces five-year overall survival rates commonly approaching:

70–80%, with variation across risk groups and treatment protocols.

Metastatic Disease

Overall survival is substantially lower, often approximately:

20–40% at five years, depending on metastatic distribution and other factors.

Lung-Only Metastases

May carry a more favorable outlook than extensive bone or marrow metastases.

Bone and Marrow Metastases

Generally associated with poorer outcomes.

Tumor Location

Pelvic and axial tumors may be harder to resect adequately and may be associated with unfavorable outcomes.

Tumor Size

Large tumors carry a higher risk of treatment failure.

Age

Older adolescent and adult age may be associated with poorer outcomes in some cohorts.

LDH

Elevated pretreatment LDH can indicate greater tumor burden and may be prognostic.

Histological Response

Extensive tumor necrosis after induction chemotherapy is generally a favorable finding.

Surgical Margins

Complete local control is important.

Recurrence

Relapsed disease has a considerably worse prognosis than newly diagnosed localized disease.

Time to Relapse

Early relapse generally carries a less favorable prognosis.

Molecular Fusion Type

The common EWSR1::FLI1 fusion subtype does not ordinarily determine prognosis or routine treatment choice.

Long-Term Survival

Some survivors experience substantial treatment-related health consequences.

Clinical Importance

Modern treatment offers a realistic possibility of cure for many children with localized Ewing sarcoma, while metastatic and relapsed disease remain major therapeutic challenges.

93. COMPLICATIONS

Local Bone Destruction

Tumor growth may weaken and destroy affected bone.

Persistent Bone Pain

Pain may impair activity, sleep, and quality of life.

Pathological Fracture

Weakened bone may break with minimal trauma.

Limb Deformity

Bone destruction or treatment may alter alignment.

Joint Dysfunction

Tumor involvement or treatment may impair range of motion.

Muscle Weakness

Pain, inactivity, surgery, and chemotherapy may cause weakness.

Gait Abnormality

Lower limb disease may produce limping or altered walking patterns.

Loss of Mobility

Severe local disease may impair ambulation.

Neurological Compression

Tumors may compress peripheral nerves or the spinal cord.

Spinal Cord Compression

May cause weakness, sensory deficits, or bladder and bowel dysfunction.

Permanent Neurological Deficit

Delayed treatment of severe compression may produce lasting impairment.

Local Vascular Compression

Tumor growth may interfere with adjacent blood vessels.

Venous Obstruction

May cause swelling or thrombosis.

Local Tumor Necrosis

Rapid growth may produce necrotic tissue.

Tumor-Associated Hemorrhage

Bleeding may occur within or around a tumor.

Metastatic Pulmonary Disease

May cause respiratory symptoms or progressive lung dysfunction.

Bone Metastases

May produce additional painful skeletal lesions.

Metastatic Pathological Fractures

Distant skeletal deposits may weaken bone.

Bone Marrow Infiltration

May impair normal blood cell production.

Anemia

May result from marrow involvement or chemotherapy.

Thrombocytopenia

May cause bruising or bleeding.

Leukopenia

May reduce resistance to infection.

Severe Neutropenia

Myelosuppressive chemotherapy may cause profound neutrophil depletion.

Febrile Neutropenia

Requires urgent antimicrobial treatment.

Bacterial Sepsis

Immunosuppression may predispose to severe bloodstream infection.

Fungal Infection

Prolonged neutropenia increases risk of invasive fungal disease.

Septic Shock

Severe infection may cause circulatory failure.

Central Venous Catheter Infection

Indwelling devices may become infected.

Catheter-Associated Thrombosis

Central lines may predispose to venous clot formation.

Venous Thromboembolism

Cancer and treatment may increase thrombosis risk.

Pulmonary Embolism

Venous clots may migrate to the lungs.

Alopecia

Chemotherapy commonly causes temporary hair loss.

Nausea and Vomiting

May be severe without effective antiemetic prophylaxis.

Dehydration

Gastrointestinal toxicity may reduce fluid intake.

Mucositis

Chemotherapy may cause painful oral and gastrointestinal inflammation.

Esophagitis

Mucosal injury may impair swallowing.

Diarrhea

Chemotherapy or infection may cause gastrointestinal symptoms.

Constipation

May result from vincristine, opioid treatment, or reduced mobility.

Ileus

Vincristine-related autonomic neuropathy may impair intestinal motility.

Peripheral Neuropathy

Vincristine may cause sensory or motor nerve injury.

Foot Drop

Severe neuropathy may impair dorsiflexion.

Jaw Pain

May occur with vincristine-associated neuropathy.

Autonomic Neuropathy

Can affect bowel and bladder function.

Hemorrhagic Cystitis

Cyclophosphamide or ifosfamide metabolites may injure the bladder.

Hematuria

May result from urinary tract toxicity.

Bladder Fibrosis

Severe recurrent bladder injury may cause chronic dysfunction.

Renal Tubular Injury

Ifosfamide may impair proximal tubular function.

Fanconi Syndrome

May cause urinary losses of glucose, phosphate, bicarbonate, and other solutes.

Hypophosphatemia

Can develop from renal phosphate wasting.

Hypokalemia

May occur with renal tubular toxicity.

Metabolic Acidosis

Renal tubular dysfunction may impair acid-base balance.

Acute Kidney Injury

May result from chemotherapy, dehydration, infection, or other causes.

Chronic Kidney Disease

Severe renal injury may produce lasting impairment.

Ifosfamide Encephalopathy

May cause confusion, somnolence, hallucinations, or seizures.

Seizures

Can result from metabolic abnormalities or drug-related neurotoxicity.

Hearing or Sensory Difficulties

May occur from selected treatments or other complications.

Anthracycline Cardiotoxicity

Doxorubicin may impair myocardial function.

Cardiomyopathy

May develop during treatment or years later.

Heart Failure

Severe cardiac dysfunction may cause clinical heart failure.

Arrhythmias

May accompany cardiac toxicity.

Radiation-Associated Cardiac Injury

Thoracic irradiation may damage cardiac structures.

Pulmonary Pneumonitis

Chest irradiation may produce inflammatory lung injury.

Pulmonary Fibrosis

Radiation may cause persistent lung scarring.

Reduced Lung Capacity

Thoracic surgery or irradiation may impair pulmonary function.

Chest Wall Deformity

Resection or irradiation during growth may alter thoracic development.

Impaired Growth of Irradiated Bone

Radiation may affect growth plates and bone development.

Limb-Length Discrepancy

Surgery or radiation may alter growth in one limb.

Joint Contracture

Immobilization and fibrosis may limit movement.

Radiation Fibrosis

May cause tissue stiffness and reduced function.

Radiation Dermatitis

May cause erythema, pain, and skin injury.

Skin Breakdown

Severe local treatment effects may impair wound integrity.

Wound Dehiscence

Surgical wounds may separate.

Surgical Site Infection

May complicate reconstruction.

Osteomyelitis

Reconstructed or operated bone may become infected.

Nonunion

Reconstructed bone segments may fail to unite.

Graft Failure

Bone grafts or allografts may fail mechanically or biologically.

Endoprosthetic Failure

Implants may loosen, fracture, or become infected.

Prosthetic Revision

Growing children may require repeated reconstructive procedures.

Amputation-Related Functional Loss

May require ongoing prosthetic care.

Phantom Limb Pain

May occur after amputation.

Chronic Postsurgical Pain

May persist after local-control procedures.

Reduced Exercise Capacity

May result from deconditioning, cardiac toxicity, or musculoskeletal impairment.

Delayed Physical Development

Intensive therapy may temporarily affect normal growth and physical maturation.

Delayed Puberty

Gonadal injury or chronic illness may delay pubertal progression.

Ovarian Insufficiency

Gonadotoxic treatment may impair ovarian function.

Testicular Dysfunction

Alkylating agents may impair sperm production or hormonal function.

Reduced Fertility

May occur after chemotherapy or gonadal irradiation.

Premature Menopause

May result from severe ovarian injury.

Pregnancy-Related Risks

Certain treatment exposures may affect future reproductive health.

Endocrine Dysfunction

Radiotherapy or systemic effects may impair selected endocrine organs.

Reduced Bone Mineral Density

May result from treatment, immobility, endocrine abnormalities, or malnutrition.

Osteopenia

Low bone density may increase fracture risk.

Osteoporosis

May occur in selected long-term survivors.

Avascular Necrosis

May develop in selected treatment circumstances.

Secondary Myelodysplastic Syndrome

May occur after exposure to leukemogenic chemotherapy.

Therapy-Related Acute Myeloid Leukemia

A recognized rare late complication.

Radiation-Associated Sarcoma

May arise within a previously irradiated field years later.

Other Second Malignancies

Risk depends on chemotherapy and radiotherapy exposure.

Local Recurrence

Tumor may reappear at the original site.

Pulmonary Relapse

Recurrent metastatic disease may involve the lungs.

Skeletal Relapse

New or recurrent bone lesions may develop.

Multifocal Relapse

Disease may recur at several sites.

Treatment-Resistant Disease

Some tumors fail to respond adequately to standard chemotherapy.

Progressive Metastatic Disease

May cause multisystem morbidity.

Chronic Cancer-Related Pain

May require long-term multidisciplinary management.

Fatigue

Can persist during or after treatment.

Malnutrition

May result from treatment toxicity or reduced intake.

Anxiety

May occur during diagnosis, treatment, and survivorship.

Depression

Cancer-related distress may impair emotional well-being.

Body Image Distress

Surgery, alopecia, and visible changes may affect self-confidence.

Posttraumatic Stress Symptoms

Some patients and families develop significant treatment-related psychological distress.

School Absenteeism

Treatment may interrupt education.

Learning Difficulties

Fatigue, hospitalization, and psychosocial stress may impair academic performance.

Social Isolation

Treatment precautions and limited mobility may restrict peer interaction.

Financial Toxicity

Cancer treatment can place substantial financial pressure on families.

Caregiver Burnout

Long-term treatment demands may affect caregiver health.

Reduced Quality of Life

May result from functional limitations and treatment late effects.

Premature Mortality

May result from progressive disease, serious treatment toxicity, or late complications.

Death

Ewing sarcoma can be fatal, particularly in metastatic, treatment-resistant, or recurrent disease.


Image description
0 Comments